US equities |
NVDA $186.64 ▲+2.78% MU $690.00 ▲+5.12% AMD $449.04 ▲+11.04% SPCX $134.27 ▲+8.62% AAPL $342.37 ▼-0.52% SNDK $835.06 ▲+3.55% MSFT $530.61 ▼-0.99% TSLA $358.22 ▲+4.23%
FinancialContent

Evommune, Inc. Common Stock (NY:EVMN)

6.650 +0.280 (+4.40%)
Official Closing Price Updated: 7:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evommune, Inc. Common Stock

< Previous 1 2 Next >
News headline image
Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development ↗
Evommune (NYSE:EVMN) has licensed global development rights outside Greater China to EVO570, an experimental oral drug for inflammatory diseases, in a deal with Hinova Pharmaceuticals that includes $20... 
Via MarketBeat
Topics Intellectual Property
News headline image
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Announces $30 Million Private Placement
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
From Evommune, Inc.
Via Business Wire
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? ↗
Via Stocktwits
News headline image
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
From Evommune, Inc.
Via Business Wire
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
From Evommune, Inc.
Via Business Wire
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
From Evommune, Inc.
Via Business Wire
News headline image
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
From Evommune, Inc.
Via Business Wire
News headline image
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade ↗
Evommune has two autoimmune disorder treatments with blockbuster potential. 
Via The Motley Fool
News headline image
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
From Evommune, Inc.
Via Business Wire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
Evommune Announces $125 Million Private Placement
From Evommune, Inc.
Via Business Wire
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
From Evommune, Inc.
Via Business Wire
News headline image
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗
Via MarketBeat
< Previous 1 2 Next >